The efficacy and safety of the most practicable strategies for the ongoing COVID‐19 are urgently needed to be further assessed in clinical trials, involving remdesivir (GS‐5734), lopinavir/ritonavir, lopinavir/ritonavir combined with IFN‐β, convalescent plasma, and mAbs, which prove to be potentially effective options against SARS‐CoV‐2. This evidence concerns the gene IFNB1 and COVID-19.